Abstract
Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.
| Original language | English |
|---|---|
| Pages (from-to) | 302-306 |
| Number of pages | 5 |
| Journal | Journal of the Peripheral Nervous System |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Dec 2010 |
Fingerprint
Keywords
- antibodies
- ganglioside complexes
- GQ1b
- IgM
- MAG
- monoclonal gammopathy
- neuropathy
- rituximab
- sulfatide
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010). / Nobile-Orazio, Eduardo.
In: Journal of the Peripheral Nervous System, Vol. 15, No. 4, 12.2010, p. 302-306.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010)
AU - Nobile-Orazio, Eduardo
PY - 2010/12
Y1 - 2010/12
N2 - Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.
AB - Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.
KW - antibodies
KW - ganglioside complexes
KW - GQ1b
KW - IgM
KW - MAG
KW - monoclonal gammopathy
KW - neuropathy
KW - rituximab
KW - sulfatide
UR - http://www.scopus.com/inward/record.url?scp=78650805520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650805520&partnerID=8YFLogxK
U2 - 10.1111/j.1529-8027.2010.00283.x
DO - 10.1111/j.1529-8027.2010.00283.x
M3 - Article
C2 - 21199101
AN - SCOPUS:78650805520
VL - 15
SP - 302
EP - 306
JO - Journal of the Peripheral Nervous System
JF - Journal of the Peripheral Nervous System
SN - 1085-9489
IS - 4
ER -